Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction
- 1 May 2003
- Vol. 123 (5) , 1583-1588
- https://doi.org/10.1378/chest.123.5.1583
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-Term Outcome after Pulmonary ThromboendarterectomyAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Orally active prostacyclin analogue in primary pulmonary hypertensionThe Lancet, 1997
- The management of pulmonary hypertension secondary to chronic thromboembolic diseaseProgress in Cardiovascular Diseases, 1994
- Orally Administered Beraprost Sodium Inhibits Pulmonary Hypertension Induced by Monocrotaline in Rats.The Tohoku Journal of Experimental Medicine, 1994
- Pulmonary Vascular Lesions Occurring in Patients With Chronic Major Vessel Thromboembolic Pulmonary HypertensionChest, 1993
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992
- Chronic major-vessel thromboembolic pulmonary hypertension.Circulation, 1990
- Longterm Follow-up of Patients with Pulmonary ThromboembolismChest, 1982
- Reliability of the Determination of Cardiac Output in Man by Means of the Fick PrincipleCirculation Research, 1958